Literature DB >> 14587005

Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues.

Mark G Swanson1, Daniel B Vigneron, Z Laura Tabatabai, Ryan G Males, Lars Schmitt, Peter R Carroll, Joyce K James, Ralph E Hurd, John Kurhanewicz.   

Abstract

Proton high-resolution magic angle spinning ((1)H HR-MAS) NMR spectroscopy and quantitative histopathology were performed on the same 54 MRI/3D-MRSI-targeted postsurgical prostate tissue samples. Presurgical MRI/3D-MRSI targeted healthy and malignant prostate tissues with an accuracy of 81%. Even in the presence of substantial tissue heterogeneity, distinct (1)H HR-MAS spectral patterns were observed for different benign tissue types and prostate cancer. Specifically, healthy glandular tissue was discriminated from prostate cancer based on significantly higher levels of citrate (P = 0.04) and polyamines (P = 0.01), and lower (P = 0.02) levels of the choline-containing compounds choline, phosphocholine (PC), and glycerophosphocholine (GPC). Predominantly stromal tissue lacked both citrate and polyamines, but demonstrated significantly (P = 0.01) lower levels of choline compounds than cancer. In addition, taurine, myo-inositol, and scyllo-inositol were all higher in prostate cancer vs. healthy glandular and stromal tissues. Among cancer samples, larger increases in choline, and decreases in citrate and polyamines (P = 0.05) were observed with more aggressive cancers, and a MIB-1 labeling index correlated (r = 0.62, P = 0.01) with elevated choline. The elucidation of spectral patterns associated with mixtures of different prostate tissue types and cancer grades, and the inclusion of new metabolic markers for prostate cancer may significantly improve the clinical interpretation of in vivo prostate MRSI data. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14587005     DOI: 10.1002/mrm.10614

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  78 in total

Review 1.  Application of metabolomics to prostate cancer.

Authors:  Bruce J Trock
Journal:  Urol Oncol       Date:  2011 Sep-Oct       Impact factor: 3.498

Review 2.  Magnetic resonance spectroscopy: a promising tool for the diagnostics of human prostate cancer?

Authors:  Johannes Kurth; Elita Defeo; Leo L Cheng
Journal:  Urol Oncol       Date:  2011 Sep-Oct       Impact factor: 3.498

3.  High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues.

Authors:  Olaf Beckonert; Muireann Coen; Hector C Keun; Yulan Wang; Timothy M D Ebbels; Elaine Holmes; John C Lindon; Jeremy K Nicholson
Journal:  Nat Protoc       Date:  2010-05-13       Impact factor: 13.491

Review 4.  Metabonomics techniques and applications to pharmaceutical research & development.

Authors:  John C Lindon; Elaine Holmes; Jeremy K Nicholson
Journal:  Pharm Res       Date:  2006-05-25       Impact factor: 4.200

5.  Two-dimensional MR spectroscopy of healthy and cancerous prostates in vivo.

Authors:  M Albert Thomas; Thomas Lange; S Sendhil Velan; Rajakumar Nagarajan; Steve Raman; Ana Gomez; Daniel Margolis; Stephany Swart; Raymond R Raylman; Rolf F Schulte; Peter Boesiger
Journal:  MAGMA       Date:  2008-07-17       Impact factor: 2.310

Review 6.  Applications of metabolomics to study cancer metabolism.

Authors:  Akash K Kaushik; Ralph J DeBerardinis
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-04-25       Impact factor: 10.680

7.  Evaluation of the ERETIC method as an improved quantitative reference for 1H HR-MAS spectroscopy of prostate tissue.

Authors:  Mark J Albers; Thomas N Butler; Iman Rahwa; Nguyen Bao; Kayvan R Keshari; Mark G Swanson; John Kurhanewicz
Journal:  Magn Reson Med       Date:  2009-03       Impact factor: 4.668

Review 8.  Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis.

Authors:  Martin Umbehr; Lucas M Bachmann; Ulrike Held; Thomas M Kessler; Tullio Sulser; Dominik Weishaupt; John Kurhanewicz; Johann Steurer
Journal:  Eur Urol       Date:  2008-10-18       Impact factor: 20.096

Review 9.  Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence.

Authors:  Rachel S Kelly; Matthew G Vander Heiden; Edward Giovannucci; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-04-06       Impact factor: 4.254

10.  Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor.

Authors:  Kayvan R Keshari; Renuka Sriram; Mark Van Criekinge; David M Wilson; Zhen J Wang; Daniel B Vigneron; Donna M Peehl; John Kurhanewicz
Journal:  Prostate       Date:  2013-03-26       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.